FENC
Companies
NASDAQ
Fennec Pharmaceuticals Inc.
Health Care
$7.86
+$1.54 (+24.37%)
Price Chart
Overview
About FENC
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
Market Cap
$187.4M
Volume
516.2K
Avg. Volume
549.2K
P/E Ratio
18.486486
Dividend Yield
0.00%
Employees
29.0
Company Information
Risk & Correlation Analysis
Market Correlation
0.94
Moderate Correlation
Volatility
High (0.56)
Relative to market
Macro Factor Sensitivities
Interest Rates
Medium Sensitivity
Inflation
Medium Sensitivity
GDP Growth
Low Sensitivity
Liquidity
Medium Sensitivity
Commodity Prices
Medium Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, FENC shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$187.4M
Volume516.2K
P/E Ratio18.49
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 13, 2025Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025